Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations
- PMID: 16923573
- DOI: 10.1080/10428190600565925
Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations
Abstract
RAS genes, predominantly N-RAS and K-RAS, have been implicated in the pathogenesis of acute myeloid leukemia (AML), due to activating RAS mutations detectable in approximately 20% of AML patients. In the present study, RAS proteins were detected in their activated, GTP-bound form, in AML patients (n = 10) not expressing mutated forms of H-RAS, K-RAS and N-RAS. Further analysis revealed the simultaneous presence of N-RAS and K-RAS proteins in the GTP-bound state in seven out of 10 AML samples. In four out of 10 samples the levels of RAS-GTP were comparable to an AML cell line (TF-1) with an activating N-RAS mutation (Q61P). The detection of RAS-GTP in AML patients without RAS mutations further supports a functional role of RAS proteins in the pathogenesis of AML and may explain the observed effects of RAS inhibitors in some AML patients in the absence of activating RAS mutations.
Similar articles
-
Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation.Ann Hematol. 2009 Apr;88(4):319-24. doi: 10.1007/s00277-008-0593-6. Epub 2008 Sep 11. Ann Hematol. 2009. PMID: 18784923 Free PMC article.
-
Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia.Ann Hematol. 2014 Jun;93(6):977-82. doi: 10.1007/s00277-014-2061-9. Epub 2014 Apr 16. Ann Hematol. 2014. PMID: 24737308
-
Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.Leukemia. 2008 Feb;22(2):303-7. doi: 10.1038/sj.leu.2404995. Epub 2007 Oct 25. Leukemia. 2008. PMID: 17960171
-
RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis.Clin Chim Acta. 2019 Feb;489:254-260. doi: 10.1016/j.cca.2018.08.040. Epub 2018 Sep 6. Clin Chim Acta. 2019. PMID: 30194935 Review.
-
NF1 inactivation revs up Ras in adult acute myelogenous leukemia.Clin Cancer Res. 2010 Aug 15;16(16):4074-6. doi: 10.1158/1078-0432.CCR-10-1438. Epub 2010 Jun 29. Clin Cancer Res. 2010. PMID: 20587590 Review.
Cited by
-
The effects of mutant Ras proteins on the cell signalome.Cancer Metastasis Rev. 2020 Dec;39(4):1051-1065. doi: 10.1007/s10555-020-09912-8. Cancer Metastasis Rev. 2020. PMID: 32648136 Free PMC article. Review.
-
An elaborate pathway required for Ras-mediated epigenetic silencing.Nature. 2007 Oct 25;449(7165):1073-7. doi: 10.1038/nature06251. Nature. 2007. PMID: 17960246 Free PMC article.
-
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.Int J Hematol. 2019 Aug;110(2):213-227. doi: 10.1007/s12185-019-02667-1. Epub 2019 May 25. Int J Hematol. 2019. PMID: 31129802
-
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.Expert Opin Investig Drugs. 2010 May;19(5):689-98. doi: 10.1517/13543781003801076. Expert Opin Investig Drugs. 2010. PMID: 20402600 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous